Immutep's Losses Widen 44% Amid Escalating R&D Costs

TL;DR

**Immutep's deepening losses signal a tough road ahead, making it a speculative bet until a product hits the market.**

AI Summary

IMMUTEP Ltd (PRRUF) reported a significant increase in net losses for the fiscal year ended June 30, 2025, reaching A$61.4 million, up from A$42.7 million in 2024, reflecting a 43.8% increase. The company, a development-stage biotech, continues to incur substantial operating losses and negative cash flows, with no medicinal products approved for commercial sale and no material revenue from product sales. Its business is heavily dependent on the future success of five LAG-3 related product candidates, including the most advanced, eftilagimod alfa (efti), which is in Phase II and Phase III clinical trials with partners like Merck & Co. and Merck KGaA/Pfizer. IMMUTEP anticipates further increases in expenses due to ongoing clinical trials for efti and IMP761, as well as research and preclinical development. The company will require additional financing through public or private funding, or licensing arrangements, to support its long-term goals of commercialization and further development, as current funding sources are insufficient to cover anticipated rising costs.

Why It Matters

Immutep's widening net losses and reliance on future product candidate success pose a significant challenge for investors, indicating a high-risk, high-reward profile typical of development-stage biotechs. The company's strategic collaborations with pharmaceutical giants like Merck & Co. and Novartis for its LAG-3 product candidates, such as efti and IMP701, are crucial for validating its technology and potentially accelerating market entry. However, the lack of approved products and consistent revenue means employees' job security and customers' access to potential therapies hinge entirely on successful clinical trials and regulatory approvals. In a competitive immuno-oncology landscape, Immutep's ability to secure additional financing and advance its pipeline will determine its long-term viability and impact on the broader market.

Risk Assessment

Risk Level: high — The company reported net losses of A$61.4 million for the fiscal year ended June 30, 2025, a substantial increase from A$42.7 million in 2024. This 43.8% increase in losses, coupled with the explicit statement that 'We have no medicinal products approved for commercial sale and no source of consistent material revenue,' indicates a high financial risk. The filing also states, 'We expect to continue to incur losses from operations for the foreseeable future and expect the costs of drug development to increase in the future,' highlighting ongoing financial vulnerability.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor closely for updates on clinical trial progress for eftilagimod alfa and any new financing rounds, as these will be critical indicators of the company's ability to sustain operations and potentially achieve profitability.

Financial Highlights

debt To Equity

N/A

revenue

A$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

A$-61.4M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $61.4M — Net Loss (Increased from A$42.7 million in FY2024, representing a 43.8% rise in losses for FY2025.)
• 1,460,389,575 — Ordinary Shares Outstanding (As of June 30, 2025, indicating the current share count.)
• 10 — Ordinary Shares per ADS (Each American Depositary Share represents 10 ordinary shares.)
• 5 — LAG-3 Product Candidates (The total number of product candidates in Immutep's pipeline, including efti and IMP761.)

Key Players & Entities

• IMMUTEP Ltd (company) — Registrant
• Marc Voigt (person) — Chief Executive Officer
• Merck & Co., Inc. (company) — Clinical trial collaboration partner for efti
• Merck KGaA (company) — Clinical trial collaboration partner for efti
• Pfizer (company) — Clinical trial collaboration partner for efti
• Novartis (company) — Licensee for IMP701 (ieramilimab)
• EOC Pharma (company) — Licensee for efti in China
• A$61.4 million (dollar_amount) — Net loss for fiscal year ended June 30, 2025
• A$42.7 million (dollar_amount) — Net loss for fiscal year ended June 30, 2024
• The Bank of New York Mellon (company) — Depositary for ADSs

FAQ

Risk Factors

• Significant Net Losses and Negative Cash Flow [high — financial]: The company reported a net loss of A$61.4 million for FY2025, a 43.8% increase from A$42.7 million in FY2024. This reflects substantial operating losses and negative cash flows, characteristic of a development-stage biotech with no approved products.
• Dependence on Future Financing [high — financial]: Current funding sources are insufficient to cover anticipated rising costs associated with ongoing clinical trials and development. Immutep requires additional financing through public or private funding, or licensing arrangements, to support its long-term commercialization goals.
• Reliance on Product Candidate Success [high — operational]: The company's business is heavily dependent on the future success of its five LAG-3 related product candidates, with the most advanced, eftilagimod alfa, still in Phase II and Phase III trials. Any setbacks in these trials could significantly impact the company's prospects.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: The development of pharmaceutical products is subject to extensive clinical trials and rigorous regulatory approval processes. Delays or failures in these trials, or an inability to secure regulatory approvals for its product candidates, pose a significant risk to Immutep's commercialization strategy.

Industry Context

The biotechnology sector, particularly in oncology, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like Immutep are focused on novel immunotherapies, with a growing emphasis on combination treatments and targeting immune checkpoints like LAG-3. The competitive landscape includes large pharmaceutical companies and numerous smaller biotech firms vying for breakthroughs in cancer treatment.

Regulatory Implications

As a development-stage biotech, Immutep faces substantial regulatory risks associated with clinical trial design, patient recruitment, and the stringent approval processes of agencies like the FDA and EMA. Any delays or adverse findings in ongoing trials for eftilagimod alfa or other candidates could significantly impact the company's ability to reach commercialization.

What Investors Should Do

1. Monitor clinical trial progress and partnership updates
2. Assess future financing needs and dilution risk
3. Evaluate the competitive landscape for LAG-3 inhibitors

Glossary

LAG-3

Lymphocyte-activation gene 3, a protein found on the surface of immune cells that plays a role in regulating immune responses. Targeting LAG-3 is a strategy in cancer immunotherapy. (Immutep's pipeline is centered around LAG-3 related product candidates, making this a core area of their research and development.)

eftilagimod alfa (efti)

Immutep's lead product candidate, which is a soluble LAG-3 protein designed to activate T cells and antigen-presenting cells to fight cancer. (It is the most advanced product candidate in Immutep's pipeline, currently in Phase II and Phase III clinical trials, and is crucial to the company's future revenue potential.)

American Depositary Shares (ADSs)

A negotiable certificate issued by a U.S. depositary bank representing a specified number of ordinary shares of a foreign company. (Immutep's ADSs are listed on the NASDAQ Global Market, providing U.S. investors with a way to trade ownership in the Australian-based company.)

IFRS

International Financial Reporting Standards, a set of accounting standards developed by the International Accounting Standards Board (IASB) that are used in many countries around the world. (Immutep's consolidated financial statements are prepared in accordance with IFRS, ensuring comparability for international investors.)

Year-Over-Year Comparison

For the fiscal year ended June 30, 2025, Immutep reported a significant increase in net losses to A$61.4 million, up 43.8% from A$42.7 million in the prior year. This widening loss reflects the ongoing investment in clinical development and research, as the company continues to operate without approved products generating revenue. No material revenue growth or margin improvements are expected in the near term due to the company's development stage.

Key Financial Figures

• $61.4 million — , 2025, and 2024, we had net losses of A$61.4 million and A$42.7 million, respectively. We
• $42.7 m — e had net losses of A$61.4 million and A$42.7 million, respectively. We are a develop

Filing Documents

• d33851d20f.htm (20-F) — 3729KB
• d33851dex41.htm (EX-4.1) — 141KB
• d33851dex121.htm (EX-12.1) — 10KB
• d33851dex131.htm (EX-13.1) — 5KB
• d33851dex151.htm (EX-15.1) — 1KB
• g33851g1007175555631.jpg (GRAPHIC) — 108KB
• 0001193125-25-249346.txt ( ) — 17546KB
• immp-20250630.xsd (EX-101.SCH) — 2622KB
• d33851d20f_htm.xml (XML) — 4129KB

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 75 Item 12.

Description of Securities Other than Equity Securities

Description of Securities Other than Equity Securities 75 A. Debt Securities 75 B. Warrants and Rights 75 C. Other Securities 75 D. American Depositary Shares 76 PART II 78 Item 13. Defaults, Dividend Arrearages and Delinquencies 78 Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 78 Item 15.

Controls and Procedures

Controls and Procedures 78 Item 16. Reserved 79 Item 16A. Audit Committee Financial Expert 79 Item 16B. Code of Ethics 79 Item 16C. Principal Accountant Fees and Services 79 Item 16D. Exemptions from the Listing Standards for Audit Committees 79 Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 79 Item 16F. Change in Registrant's Certifying Accountant 79 Item 16G. Corporate Governance 79 Item 16H. Mine Safety Disclosure 79 Item 16I. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections 79 Item 16J Insider Trading Policies 80 Item 16K Cybersecurity 80 PART III 82 Item 17.

Financial Statements

Financial Statements 82 Item 18.

Financial Statements

Financial Statements 82 Item 19. Exhibits ii Table of Contents INTRODUCTION Immutep Limited (ABN 90 009 237 889) was incorporated under the laws of the Commonwealth of Australia on May 21, 1987. The principal listing of our ordinary shares is the Australian Securities Exchange, or ASX. We filed a registration statement on Form 20-F with respect to our ordinary shares with the U.S. Securities and Exchange Commission, or SEC, which was declared effective on April 12, 2012. Our American Depositary Shares, or ADSs, each of which represents 10 of our ordinary shares, are listed on the NASDAQ Global Market, or NASDAQ, under the symbol "IMMP". The Bank of New York Mellon acts as our depositary and registers and delivers our ADSs. As used in this Annual Report on Form 20-F, the terms "we," "us," "our", "Immutep" and the "Company" mean Immutep Limited and its subsidiaries, unless otherwise indicated. FINANCIAL AND OTHER INFORMATION Our consolidated financial statements appearing in this Annual Report on Form 20-F are prepared in Australian dollars and in accordance with the International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. Our consolidated financial statements appearing in this Annual Report on Form 20-F comply with both the IFRS and Australian Accounting Standards. In this Annual Report, all references to "U.S. dollars" or "US

View Full Filing

View this 20-F filing on SEC EDGAR